■代谢相关脂肪性肝病(MAFLD)是慢性肝病的主要原因。如今,墨西哥MAFLD的患病率未知,没有筛查点护理工具.我们旨在评估墨西哥MAFLD的患病率,并制定MAFLD筛查评分。
■我们在墨西哥5个州进行了一项横断面研究,包括在体检活动中评估的成人受试者。受试者接受肝脏超声检查以寻找肝性脂肪变性。根据与MAFLD相关的临床相关变量,我们制定了MAFLD筛查评分(MAFLD-S).使用ROC曲线下面积和观察与预测图评估评分的区分和校准,分别。
■我们包括3357名参与者(60%为女性,平均年龄47±12岁)。52%有肝脏脂肪变性,47%符合MAFLD标准。MAFLD患者年龄较大(48±11vs45±13岁,P<.001),更常见的是男性(43%vs36%,P<.001),与没有MAFLD的受试者相比,体重指数更高(31.64.9vs25.63.8kg/m2,P<.001)。MAFLD-S包括年龄,身体质量指数,性别,糖尿病,高血压,和血脂异常,曲线下面积为0.852,95%CI=0.828-0.877,最佳临界值的敏感性为78.8%,特异性为82.8%。使用2018-2019年国家健康和营养调查的数据,我们预测MAFLD全国患病率为49.6%。
■近一半的墨西哥人口患有MAFLD,代表着当前和未来的挑战。通过外部验证,MAFLD-S可能是一种有价值和实用的筛查工具。
UNASSIGNED: Metabolic-associated fatty liver disease (MAFLD) is a leading cause of chronic liver disease. Nowadays, the prevalence of MAFLD in Mexico is unknown with no screening point-of-care tools. We aimed to estimate the prevalence of MAFLD in Mexico and to develop a score for MAFLD screening.
UNASSIGNED: We conducted a cross-sectional study in 5 Mexican states, including adult subjects evaluated in checkup campaigns. Subjects underwent a liver ultrasound to look for hepatic steatosis. Based on the most clinically relevant variables associated with MAFLD, we developed the MAFLD-screening score (MAFLD-S). Discrimination and calibration of the score were evaluated using the area under the ROC curve and observed vs predicted plots, respectively.
UNASSIGNED: We included 3357 participants (60% female, mean age 47 ± 12 years). Fifty-two percent had hepatic steatosis, and 47% met MAFLD criteria. Subjects with MAFLD were older (48 ± 11 vs 45 ± 13 years, P < .001), were more frequently males (43% vs 36%, P < .001), and had a higher body mass index (31.6 + 4.9 vs 25.6 + 3.8 kg/m2, P < .001) than subjects without MAFLD. The MAFLD-S includes age, body mass index, gender, diabetes, hypertension, and dyslipidemia and has an area under the curve of 0.852, 95% CI = 0.828-0.877, with a sensitivity of 78.8% and a specificity of 82.8% for the optimal cutoff. Using data from the National Health and Nutrition Survey 2018-2019, we predicted a MAFLD national prevalence of 49.6%.
UNASSIGNED: Nearly half of the Mexican population has MAFLD, representing a present and future challenge. With external validation, the MAFLD-S could be a valuable and practical screening tool.